Review of a New Multimodal Antidepressant Vortioxetine
Acta Medica Martiniana · 2016
DOI: 10.1515/acm-2016-0011 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Medica Martiniana, 2016. Verfasst von M Oppa und 3 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 3.0).
Abstract (Originalsprache)
Vortioxetine is a novel antidepressant with two mechanisms of action – direct effect on several serotonin receptors and serotonin re-uptake inhibition. It shows antidepressant, anxiolytic and cognitive effects during the treatment of major depressive disorder (MDD). The aim of this article was to summarize the use of vortioxetine in clinical studies and assess the efficacy and tolerability. Most of the studies reported a statistically significant efficacy for vortioxetine versus placebo. In addition, vortioxetine showed efficacy in patients with an inadequate response to selective serotonin re-uptake inhibitors (SSRI) or serotonin-noradrenaline re-uptake inhibitors (SNRI) monotherapy and improved cognitive function in patients with MDD. In these studies, vortioxetine was well tolerated – most common observed adverse effect was nausea – and it was not associated with clinically important changes in laboratory test results or vital signs. Vortioxetine showed a relatively low incidence of sexual dysfunction.
Zitieren
APA
Oppa, M., Cesnekova, D., Nosalova, G., & Ondrejka, I. (2016). Review of a New Multimodal Antidepressant Vortioxetine. Acta Medica Martiniana. https://doi.org/10.1515/acm-2016-0011
Vancouver
Oppa M, Cesnekova D, Nosalova G, Ondrejka I. Review of a New Multimodal Antidepressant Vortioxetine. Acta Medica Martiniana. 2016. doi:10.1515/acm-2016-0011
BibTeX
@article{Oppa2016,
author = {Oppa, M and Cesnekova, D and Nosalova, G and Ondrejka, I},
title = {Review of a New Multimodal Antidepressant Vortioxetine},
journal = {Acta Medica Martiniana},
year = {2016},
doi = {10.1515/acm-2016-0011}
}
EUVIMED